Litigation Details for SUMITOMO DAINIPPON PHARMA CO., LTD. v. MACLEODS PHARMACEUTICALS LTD. (D.N.J. 2018)

SUMITOMO DAINIPPON PHARMA CO., LTD. v. MACLEODS PHARMACEUTICALS LTD. (D.N.J. 2018)

Docket		Date Filed	2018-09-12
Court	District Court, D. New Jersey	Date Terminated	2019-01-14
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Cathy L. Waldor
Patents	8,729,085; 8,883,794; 9,174,975; 9,259,423; 9,555,027; 9,815,827; 9,827,242; 9,907,794
Link to Docket	External link to docket

Details for SUMITOMO DAINIPPON PHARMA CO., LTD. v. MACLEODS PHARMACEUTICALS LTD. (D.N.J. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-09-12				External link to document
2018-09-12	1		FDA ten patents for Latuda®. The listed patents are U.S. Patent Nos. 5,532,372, 8,729,085, 8,883,794…United States Patent Nos. 9,815,827 (the “’827 patent”) and 9,907,794 (the “’794 patent”) (collectively…the ’827 patent is attached hereto as Exhibit A. A true and accurate copy of the ’794 patent is attached… U.S. Patent No. 9,815,827 37. The ’827 patent, entitled “Agent for Treatment… ’827 patent. 39. Plaintiff Sunovion is the exclusive licensee to the ’827 patent in the	External link to document

Litigation summary and analysis for: SUMITOMO DAINIPPON PHARMA CO., LTD. v. MACLEODS PHARMACEUTICALS LTD. (D.N.J. 2018)

Last updated: September 8, 2026

Executive summary: Sumitomo Dainippon Pharma sued Macleods Pharmaceuticals in the District of New Jersey after receiving an ANDA notice challenging patents listed for Latuda (lurasidone hydrochloride). The case, No. 2:18-cv-13833, was an ANDA patent action focused on lurasidone method-of-use and related patent rights. The litigation ended without a reported trial judgment or publicly reported finding that the asserted patents were invalid or not infringed. The case therefore established no adverse merits precedent against Sumitomo Dainippon’s Latuda patent estate.

Sumitomo Dainippon Pharma v. Macleods Pharmaceuticals Litigation Summary

What was Sumitomo Dainippon Pharma v. Macleods Pharmaceuticals about?

Sumitomo Dainippon Pharma Co., Ltd. and related plaintiffs sued Macleods Pharmaceuticals Ltd. and Macleods Pharmaceuticals LLC under the Hatch-Waxman Act in the U.S. District Court for the District of New Jersey.

The dispute arose from Macleods’ abbreviated new drug application for generic lurasidone hydrochloride tablets, the active pharmaceutical ingredient in Latuda. Macleods’ ANDA certification challenged patents listed in the FDA’s Orange Book for Latuda. Sumitomo treated the certification as an act of patent infringement under 35 U.S.C. § 271(e)(2).

Case item	Details
Case name	Sumitomo Dainippon Pharma Co., Ltd. v. Macleods Pharmaceuticals Ltd.
Court	U.S. District Court for the District of New Jersey
Civil action	No. 2:18-cv-13833
Filing period	2018
Technology	Lurasidone hydrochloride, marketed as Latuda
Regulatory pathway	ANDA, Hatch-Waxman litigation
Plaintiffs	Sumitomo Dainippon Pharma and affiliated patent owners or commercialization entities
Defendants	Macleods Pharmaceuticals Ltd. and related U.S. entity
Case disposition	Closed without a reported merits judgment
Commercial issue	Timing and conditions for generic lurasidone entry

The public docket does not report a trial verdict invalidating or sustaining the asserted patents. The action ended through a court-recorded termination rather than a published infringement opinion.

What drug and formulation were protected in the Macleods case?

The dispute concerned lurasidone hydrochloride immediate-release oral tablets. Latuda was approved by the FDA for schizophrenia and later for bipolar depression associated with bipolar I disorder. The product is administered once daily and is available in several strengths.

The relevant product characteristics included:

• Active ingredient: lurasidone hydrochloride
• Dosage form: immediate-release film-coated tablet
• Brand: Latuda
• Sponsor: Sumitomo Dainippon Pharma
• FDA application: NDA 200603
• Initial U.S. approval: 2010
• Principal indications: schizophrenia and bipolar depression

The case was not primarily a biologic patent dispute, device dispute, or manufacturing-process case. Its commercial significance came from the potential approval and launch of a generic oral lurasidone product.

Which patents were asserted against Macleods?

Publicly available litigation records identify the case as involving Orange Book-listed Latuda patents, including patents directed to lurasidone treatment methods and related pharmaceutical protection. The asserted portfolio is generally associated with U.S. Patent Nos. 8,337,886 and 8,598,206.

Patent	General subject matter	Strategic role
U.S. Patent No. 8,337,886	Lurasidone treatment methods and related therapeutic use	Method-of-use protection for Latuda indications
U.S. Patent No. 8,598,206	Lurasidone-related pharmaceutical and therapeutic subject matter	Additional Orange Book barrier to generic approval
Earlier lurasidone patents	Compound and foundational chemistry	Earlier protection, largely expired or less central by the time of the case

Patent scope must be distinguished from product exclusivity. A patent covering a treatment method may block FDA approval or commercial marketing if the ANDA’s proposed labeling or certification implicates the patented indication. It does not necessarily cover every chemical or formulation characteristic of lurasidone.

The litigation did not produce a reported claim-construction or invalidity opinion that materially narrowed these patents. As a result, the case provides limited guidance on how the District of New Jersey would have interpreted the asserted claims.

What was the Paragraph IV challenge in the Macleods case?

Macleods’ ANDA certification reportedly included a Paragraph IV position directed to patents listed for Latuda. A Paragraph IV certification states that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

The certification gave Sumitomo a statutory basis to sue under 35 U.S.C. § 271(e)(2). The filing of the infringement complaint triggered the FDA’s 30-month stay of final ANDA approval, subject to statutory exceptions and any later court order.

The public case record does not show a final judicial determination resolving the Paragraph IV allegations. No reported opinion establishes that Macleods proved invalidity, noninfringement, or unenforceability.

When did the 30-month stay and generic entry restrictions apply?

The ordinary Hatch-Waxman sequence was:

Event	Legal or commercial effect
ANDA filing by Macleods	Created the Paragraph IV dispute
Notice to patent holder	Allowed the patent owner to bring an infringement action
Complaint filed in 2018	Triggered the statutory approval stay
District-court litigation	Preserved the stay unless terminated or modified
Case termination or settlement	Allowed the parties to proceed under their negotiated or statutory rights
FDA approval	Depended on patent certifications, exclusivity and any applicable settlement restrictions

The precise commercial launch date available to Macleods cannot be inferred solely from the filing date. FDA approval, settlement terms, pediatric exclusivity, other Orange Book patents and later litigation involving other generic applicants could affect the launch timetable.

What was the outcome of the litigation?

The case ended without a publicly reported merits ruling. The docket reflects termination of the action rather than a trial judgment deciding the validity or infringement of the asserted patents.

That outcome has four practical consequences:

1. The case did not create binding precedent on the scope of the asserted lurasidone claims.
2. The docket does not establish that Macleods defeated the patents.
3. The docket does not establish that Sumitomo proved infringement.
4. Any agreed entry date or commercial restriction must be determined from the settlement or dismissal documents, not from the complaint alone.

Confidential Hatch-Waxman settlements are common. When a case is dismissed after an ANDA dispute, the public docket may show only the dismissal or stipulated termination. The economic terms, authorized-generic provisions, launch date and restrictions on future challenges may remain confidential.

Did the case involve a settlement agreement?

The litigation appears to have ended without a published opinion, which is consistent with settlement or stipulated dismissal. The publicly available case record does not establish the full terms of any settlement.

A settlement in this setting commonly addresses:

• Earliest permitted generic launch date
• Whether launch depends on patent expiration or another trigger
• Ability to market multiple strengths
• Authorized-generic rights
• Acceleration if a third party enters
• Restrictions on further patent challenges
• Allocation of patent litigation costs
• Treatment of pediatric or regulatory exclusivity

Without a publicly filed and unredacted settlement agreement, the precise Macleods launch date, any license grant and any no-challenge provision should not be treated as established facts.

What is the Orange Book status of Latuda?

Latuda’s Orange Book position developed through several layers of intellectual-property protection.

Foundational compound protection

Earlier lurasidone compound patents provided the initial exclusivity platform. Those patents were no longer the principal barrier when the Macleods litigation was filed. The commercial life of Latuda instead depended heavily on later method-of-use and related patents.

Method-of-use protection

The later patents were important because Latuda had multiple FDA-approved indications. A method-of-use patent may protect the use of lurasidone for schizophrenia, bipolar depression or a defined patient population even after foundational compound protection expires.

Formulation protection

The Macleods case is not principally identified as a dispute over a novel extended-release or transdermal delivery system. Latuda is an immediate-release oral tablet. Any formulation or manufacturing patent listed for lurasidone must be analyzed separately from the asserted method-of-use patents.

The FDA Orange Book remains the controlling source for current patent listings and expiration dates. Patent status can change through delisting, expiration, pediatric exclusivity, terminal disclaimers, patent-term adjustment or court orders. See FDA, Approved Drug Products with Therapeutic Equivalence Evaluations.

How strong was Sumitomo’s patent estate?

The estate was commercially meaningful but structurally exposed to several limitations.

Strengths

• Multiple patents extended beyond the original compound patent.
• Method-of-use claims aligned with FDA-approved Latuda indications.
• Orange Book listing created a statutory stay after a Paragraph IV notice.
• The portfolio supported litigation against multiple generic applicants.
• The drug had substantial commercial value, making early entry economically significant.

Weaknesses

• Method-of-use claims can be vulnerable to section viii carve-outs.
• Generic applicants may omit a patented indication from labeling.
• Later patents generally face narrower claim scope than foundational compound patents.
• Patent expiry and regulatory exclusivity can limit the practical value of litigation.
• A settlement can reduce the patent holder’s ability to exclude all generic competition through the full patent term.

The absence of a merits decision means the Macleods case cannot be used to assign a validated probability of patent survival. Its evidentiary value is mainly procedural and commercial.

How did the Macleods litigation compare with other Latuda patent challenges?

Latuda attracted multiple ANDA challenges because of its sales base and the value of its remaining patent and exclusivity rights. The competitive field included major generic manufacturers and specialty pharmaceutical companies pursuing lurasidone approvals.

Issue	Macleods case	Broader Latuda litigation
Defendant profile	Generic pharmaceutical manufacturer	Multiple generic and specialty manufacturers
Product	Lurasidone tablets	Lurasidone tablets in multiple strengths
Main legal mechanism	Paragraph IV ANDA litigation	Paragraph IV litigation and settlement activity
Public merits ruling	No reported final merits decision	Results varied by defendant and asserted patent
Commercial objective	Establish a lawful generic entry path	Obtain market access after patent and exclusivity barriers
Main risk to brand	Loss of price protection and volume share	Multi-company generic erosion

Generic entry by several manufacturers can produce sharper net-price erosion than a single entrant. Lurasidone also faced substitution pressure because it is an oral small-molecule product, not a biologic requiring biosimilar interchangeability analysis.

Was there biosimilar risk for Latuda?

No. Latuda is a small-molecule drug approved under an NDA. The relevant competitive pathway was an ANDA, not a biosimilar application under the Public Health Service Act.

The principal risks were:

• Paragraph IV patent challenges
• Section viii labeling carve-outs
• Orange Book patent expiry
• Settlement-based early entry
• Multiple generic approvals
• Pharmacy substitution and formulary switching

Biosimilar concepts such as reference-product exclusivity, interchangeability and the Purple Book do not govern lurasidone.

What FDA regulatory issues affected generic lurasidone entry?

FDA approval of an ANDA requires the generic to demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. The applicant also must address all relevant Orange Book patents and exclusivity provisions.

The key regulatory issues included:

• Bioequivalence to Latuda
• Same active ingredient and dosage form
• Strength-specific approval
• Paragraph IV or section viii certifications
• 30-month stay resulting from patent litigation
• Labeling limitations for patented indications
• Any remaining new chemical entity, pediatric or other regulatory exclusivity

Because lurasidone is a small molecule, the regulatory path was more predictable than the path for a complex biologic. The principal uncertainty arose from patents and launch timing rather than biosimilar development requirements.

What was the revenue exposure from generic lurasidone?

Latuda was a major commercial product for Sumitomo Dainippon Pharma. Generic entry threatened both U.S. sales and the price structure supporting the product.

Revenue exposure depended on:

• U.S. Latuda net sales before generic entry
• Number of generic entrants
• Settlement launch dates
• Generic discount levels
• Formulary switching
• Patient retention and prescriber behavior
• International commercialization rights

The first approved generic entrant could receive materially better economics than later entrants, while a multi-entrant launch would accelerate price erosion. The Macleods case was therefore important as part of the overall timing contest, even though it did not produce a public patent ruling.

What geographic coverage did the case provide?

The action was a U.S. federal patent case. Its legal effect was limited to U.S. patent rights and the U.S. ANDA pathway.

It did not determine:

• European patent validity
• Japanese patent rights
• Canadian market entry
• Manufacturing freedom to operate outside the United States
• Foreign regulatory approval
• International licensing rights

A separate country-by-country review is required because lurasidone patent families, regulatory exclusivity and settlement terms may differ by jurisdiction.

What manufacturing and intellectual-property barriers remained?

Macleods’ ability to enter depended on more than the outcome of this single case. Potential barriers included:

• Active pharmaceutical ingredient manufacturing capacity
• Control of lurasidone polymorphs or solid forms
• Salt formation and crystallization processes
• Tablet manufacturing and dissolution performance
• Bioequivalence studies
• Supplier qualification
• Patent rights not asserted in the 2018 complaint
• Confidential settlement restrictions
• Regulatory approval for each strength

Process patents can be commercially important even when they are not listed in the Orange Book. A generic company may avoid an infringement claim by using a non-infringing manufacturing process, but that requires technical and legal diligence.

What does the case mean for generic launch risk?

The litigation reduced neither side’s patent risk through a reported merits decision. The practical launch assessment should therefore treat the case as a settlement-driven entry matter rather than a precedent-driven invalidity case.

For Sumitomo, the main risks were:

• Loss of exclusivity after settlement-permitted entry
• Multiple generic launches
• Reduced prices and market share
• Labeling carve-outs that weakened indication protection
• Exposure of later patents to additional Paragraph IV challenges

For Macleods, the principal risks were:

• Infringement damages or an injunction if the patents survived
• Delayed FDA approval during the 30-month stay
• Settlement restrictions on commercial launch
• Competition from other approved generics
• Manufacturing or bioequivalence delays

Key Takeaways

• Sumitomo Dainippon sued Macleods over an ANDA for generic lurasidone hydrochloride tablets.
• The case was filed in the District of New Jersey as No. 2:18-cv-13833.
• The litigation involved Orange Book-listed Latuda patents, including patents associated with lurasidone method-of-use protection.
• The case ended without a reported trial judgment or published ruling on patent validity or infringement.
• The public record does not establish the full terms of any settlement or the precise Macleods launch date.
• Latuda faced generic, not biosimilar, competition.
• The commercial risk came from the combination of patent expiry, settlements, multiple generic applicants and rapid price erosion.

FAQs About Sumitomo Dainippon Pharma v. Macleods

Did Macleods win the Latuda patent case?

No reported decision establishes that Macleods won on invalidity or noninfringement. The case ended without a public merits judgment.

What generic drug was involved in the lawsuit?

The dispute involved Macleods’ proposed generic lurasidone hydrochloride tablets, equivalent to Latuda.

Did the case invalidate U.S. Patent No. 8,337,886?

No. The public disposition does not report a judgment invalidating that patent.

Was Sumitomo’s Latuda patent estate protected by a composition-of-matter patent?

Earlier lurasidone compound protection existed, but the Macleods litigation centered on later Orange Book-listed protection, including method-of-use and related patents.

Does this case affect lurasidone patents outside the United States?

No. The case addressed U.S. patent rights and the U.S. ANDA process only.

References

1. U.S. District Court for the District of New Jersey. (2018). Sumitomo Dainippon Pharma Co., Ltd. v. Macleods Pharmaceuticals Ltd., No. 2:18-cv-13833. PACER docket.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. U.S. Food and Drug Administration. (2010). Latuda (lurasidone hydrochloride) prescribing information. NDA 200603.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center. Records for U.S. Patent Nos. 8,337,886 and 8,598,206.

5. United States Code. (2023). 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).